Loading...
Loading...
HZNP| Name | Value |
|---|---|
| Revenues | 876.4M |
| Cost of Revenue | 230.2M |
| Gross Profit | 646.2M |
| Operating Expense | 501.5M |
| Operating I/L | 142.3M |
| Other Income/Expense | -77.6M |
| Interest Income | 0.0M |
| Pretax | 64.8M |
| Income Tax Expense | 3.8M |
| Net Income/Loss | 61.0M |
Horizon Therapeutics Public Limited Company is a biotechnology company specializing in the discovery, development, and commercialization of medicines for rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation, and markets a portfolio of 12 medicines in areas such as rare diseases, gout, ophthalmology, and inflammation. Their products include TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA, PENNSAID, DUEXIS, RAYOS, and VIMOVO, generating revenue through the sale of these medicines.
